k22

BN80933 is a dual inhibitor of lipid peroxidation and neuronal nitric oxide synthase; Neuroprotectant.

ZIKV-IN-K22 is a potent antiviral agent against a broad range of coronaviruses by targeting membrane-bound viral RNA replication, effectively inhibiting ZIKV with IC50 of 2.1 μM.

GSK2292767 is a potent and selective inhibitor of PI3Kδ.

GSK2292767 FA is a potent and selective inhibitor of PI3Kδ (pIC50 : 10.1).GSK2292767 FA is more than 500-fold more selective than other PI3K isoforms.GSK2292767 FA can be used in the study of respiratory diseases.

GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

GSK2256294A (GSK 2256294) is potent, selective inhibitor of recombinant human, rat and mouse sEH with IC50 of 27 pM, 61 pM and 189 pM, respectively.

Adenosine 5'-methylenediphosphate (sodium salt) is also referred to as an inhibitor of ecto-5'-nucleotidase.

M4K2281 is a potent and selective inhibitor of ALK2 with a half-maximal inhibitory concentration (IC50) of 2 nanomolar. In both biochemical and cellular assays, M4K2281 and M4K2308 demonstrate strong efficacy against ALK2. Moreover, M4K2281 exhibits a brain-to-plasma ratio that ranges from moderate to high.

SK2220691 is a potent TRPV4 inhibitor. It effectively suppresses pulmonary edema induced by GSK1016790. Additionally, SK2220691 inhibits the increase of crucial factors such as VEGF, keratinocyte-derived chemokine (KC; CXCL1), and granulocyte colony-stimulating factor (GCSF) induced by hydrochloric acid.

GSK2256098 (GTPL7939) is a small molecule FAK kinase inhibitor.

GSK223 is an iE-DAP-stimulated IL-8 release inhibitor via the NOD1 signaling pathway.

GSK2210875 is a mGluR5 antagonist with oral activity.

GSK2263167 is an agonist of S1P1 receptor.

GSK2200150A is an anti-tuberculosis (TB) agent identified by high-throughput screening (HTS) campaign.

GSK2239633 is a potent CC-chemokine receptor 4 antagonist with pIC50 of 7.9. The CC-chemokine receptor 4 (CCR4) is thought potentially to play a critical role in asthma pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways. Therefore, CCR4 provides an excellent target for anti-inflammatory therapy.

M4K2234 (Compound 26b) is a selective inhibitor of ALK2, displaying IC50 values of 5 nM for ALK2 and 2144 nM for ALK5. As a chemical probe for ALK1 and ALK2 kinases, it is used in mechanistic studies of BMP signaling and in cancer research where dysregulated ALK2 activity is implicated. Its high selectivity profile supports targeted investigations into ALK-mediated pathways.

Anti-MouseRANKL/CD254Antibody (IK22/5) is a rat-derived IgG2a, κ antibody inhibitor targeting the mouse RANKL/CD254.

MK-2206 dihydrochloride (MK-2206 2HCl) is a variant Akt inhibitor that inhibits Akt1, Akt2, and Akt3 (IC50=8/12/65 nM) with orally active, highly potent and selective potency. MK-2206 dihydrochloride exhibits antitumor activity.

Romidepsin (FR 901228) is an HDAC inhibitor that inhibits HDAC1/2/4/6 (IC50=36/47/510/1400 nM). Romidepsin has antitumor activity and can be used for the treatment of peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

SRT 2104 (GSK2245840) is a selective and brain-permeable SIRT1 activator.

UK 227786 is an inhibitor of phosphodiesterase 5 (PDE5), used for treatment of prostatic diseases.

Nemiralisib(GSK-2269557 free base) is an orally available, potent and specific PI3Kδ inhibitor with a pKi of 9.9.Nemiralisib is used for the treatment of respiratory diseases including chronic obstructive pulmonary disease.

Fosdevirine (GSK2248761) is a selective and potent non-nucleoside reverse transcriptase (NNRTI) inhibitor with anti-HIV activity for the study of neurological related disorders such as late-onset epilepsy.